View Item 

Show simple item record

Bortezomib‐Induced Sweet's Syndrome Confirmed by Rechallenge

dc.contributor.authorZobniw, Chrystia M.en_US
dc.contributor.authorSaad, Samira A.en_US
dc.contributor.authorKostoff, Dianaen_US
dc.contributor.authorBarthel, Bernd G.en_US
dc.date.accessioned2014-05-23T15:59:28Z
dc.date.available2015-06-01T15:48:46Zen_US
dc.date.issued2014-04en_US
dc.identifier.citationZobniw, Chrystia M.; Saad, Samira A.; Kostoff, Diana; Barthel, Bernd G. (2014). "Bortezomib‐Induced Sweet's Syndrome Confirmed by Rechallenge." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 34(4): e18-e21.en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/106899
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherInTechen_US
dc.subject.otherDrug Induceden_US
dc.subject.otherAdverse Reaction Multiple Myelomaen_US
dc.subject.otherRechallengeen_US
dc.subject.otherBortezomiben_US
dc.subject.otherSweet's Syndromeen_US
dc.titleBortezomib‐Induced Sweet's Syndrome Confirmed by Rechallengeen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/106899/1/phar1383.pdf
dc.identifier.doi10.1002/phar.1383en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferencePaydas S. Sweet's syndrome: a revisit for hematologists and oncologists. Crit Rev Oncol Hematol 2013; 86: 85 – 95.en_US
dc.identifier.citedreferenceVillarrubia B, Betlloch I, Mataix J, Lucas A, Botella C. Bortezomib associated rash: a new recognizable and avoidable side‐effect. Br J Dermatol 2007; 156: 784 – 5.en_US
dc.identifier.citedreferenceMillennium Pharmaceuticals. Velcade (Bortezomib) package insert. Cambridge, MA: Millennium Pharmaceuticals; 2012.en_US
dc.identifier.citedreferenceRoccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006; 66: 184 – 91.en_US
dc.identifier.citedreferenceRichardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609 – 17.en_US
dc.identifier.citedreferenceGinarte M, Toribio J. Sweet syndrome. In: Huag FP, ed. Autoimmune disorders ‐ current concepts and advances from bedside to mechanistic insights. Croatia: InTech, 2011: 119 – 32.en_US
dc.identifier.citedreferenceCohen PR. Sweet's syndrome‐a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis 2007; 2: 34.en_US
dc.identifier.citedreferenceNaranjo CA, Busto U, Sellers EM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239 – 45.en_US
dc.identifier.citedreferenceMurase JE, Wu JJ, Theate I, Cole GW, Barr RJ, Dyson SW. Bortezomib‐induced histiocytoid Sweet syndrome. J Am Acad Dermatol 2009; 60: 496 – 7.en_US
dc.identifier.citedreferencePaiva CM, Kurtis B, Mekki M, Newman MA, Singhal S, Lacouture ME. Neutrophilic dermatitis associated with bortezomib in a patient with multiple myeloma. Ann Oncol 2007; 18: 1744 – 5.en_US
dc.identifier.citedreferenceGarcia‐Navarro X, Puig L, Fernández‐Figueras MT, Dalmau J, Roe E, Alomar A. Bortezomib‐associated cutaneous vasculitis. Br J Dermatol 2007; 157: 799 – 801.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phar1383.pdf
Size:
96.04KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.